Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease

被引：13

作者：

Zakerska-Banaszak, Oliwia ^{[1
]}

Lykowska-Szuber, Liliana ^{[2
]}

Walczak, Michal ^{[1
]}

Zuraszek, Joanna ^{[1
]}

Zielinska, Aleksandra ^{[1
]}

Skrzypczak-Zielinska, Marzena ^{[1
]}

机构：

[1] Polish Acad Sci, Inst Human Genet, Strzeszynska 32, PL-60479 Poznan, Poland

[2] Poznan Univ Med Sci, Dept Gastroenterol, Dietet & Internal Dis, Przybyszewskiego 49, PL-60355 Poznan, Poland

来源：

TOXICS | 2022年 / 10卷 / 04期

关键词：

thiopurines; azathioprine; mercaptopurine; thioguanine; cytotoxicity; inflammatory bowel disease; Crohn's disease; ulcerative colitis; pharmacogenetics; therapeutic drug monitoring; AZATHIOPRINE METABOLITE CONCENTRATIONS; 6-THIOGUANINE NUCLEOTIDE LEVELS; EVIDENCE-BASED CONSENSUS; TERM-FOLLOW-UP; METHYLTRANSFERASE ACTIVITY; CROHNS-DISEASE; NUDT15; POLYMORPHISMS; COMBINATION THERAPY; MASS-SPECTROMETRY; CLINICAL-RESPONSE;

D O I：

10.3390/toxics10040151

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) was confirmed more than a half-century ago. It was proven that these can be essential immunomodulatory medications. Since then, they have been used routinely to maintain remission of Crohn's disease (CD) and ulcerative colitis (UC). The cytotoxic properties of thiopurines and the numerous adverse effects of the treatment are controversial. However, the research subject of their pharmacology, therapy monitoring, and the search for predictive markers are still very relevant. In this article, we provide an overview of the current knowledge and findings in the field of thiopurines in IBD, focusing on the aspect of their cytotoxicity. Due to thiopurines' benefits in IBD therapy, it is expected that they will still constitute an essential part of the CD and UC treatment algorithm. More studies are still required on the modulation of the action of thiopurines in combination therapy and their interaction with the gut microbiota.

引用

页数：19

共 112 条

[51] Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials [J].

Jones, Jennifer L. ;

Kaplan, Gilaad G. ;

Peyrin-Biroulet, Laurent ;

Baidoo, Leonard ;

Devlin, Shane ;

Melmed, Gil Y. ;

Tanyingoh, Divine ;

Raffals, Laura ;

Irving, Peter ;

Kozuch, Patricia ;

Sparrow, Miles ;

Velayos, Fernando ;

Bressler, Brian ;

Cheifetz, Adam ;

Colombel, Jean-Frederic ;

Siegel, Corey A. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (13) :2233-+

[52] Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study [J].

Kanis, Shannon L. ;

de Lima-Karagiannis, Alison ;

de Boer, Nanne K. H. ;

van der Woude, C. Janneke .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (08) :1232-+

[53] Complete sequence-based screening of TPMT variants in the Korean population [J].

Kim, Hyun-Young ;

Lee, Soo Hyun ;

Lee, Mi-Na ;

Kim, Jong-Won ;

Kim, Young-Ho ;

Kim, Mi Jin ;

Lee, Yoo Min ;

Kang, Ben ;

Choe, Yon Ho ;

Lee, Na Hee ;

Kim, Dong Hwan ;

Yoo, Keon Hee ;

Sung, Ki Woong ;

Lee, Soo-Youn ;

Koo, Hong Hoe .

PHARMACOGENETICS AND GENOMICS, 2015, 25 (03) :143-146

[54] Hematologic Indices as Surrogate Markers for Monitoring Thiopurine Therapy in IBD [J].

Kopylov, Uri ;

Battat, Robert ;

Benmassaoud, Amine ;

Paradis-Surprenant, Laurence ;

Seidman, Ernest G. .

DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (02) :478-484

[55] Functional characterization of human xanthine oxidase allelic variants [J].

Kudo, Mutsumi ;

Moteki, Toshiko ;

Sasaki, Takamitsu ;

Konno, Yumiko ;

Ujiie, Shuta ;

Onose, Akemi ;

Mizugaki, Michinao ;

Ishikawa, Masaaki ;

Hiratsuka, Masahiro .

PHARMACOGENETICS AND GENOMICS, 2008, 18 (03) :243-251

[56] Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease [J].

Kwan, L. Y. ;

Devlin, S. M. ;

Mirocha, J. M. ;

Papadakis, K. A. .

DIGESTIVE AND LIVER DISEASE, 2008, 40 (06) :425-432

[57] High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease [J].

Larussa, Tiziana ;

Suraci, Evelina ;

Lentini, Margherita ;

Nazionale, Immacolata ;

Gallo, Luigia ;

Abenavoli, Ludovico ;

Imeneo, Maria ;

Costanzo, Francesco Saverio ;

Cuda, Giovanni ;

Luzza, Francesco .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (03) :273-277

[58] Relationship Between Azathioprine Dosage, 6-Thioguanine Nucleotide Levels, and Therapeutic Response in Pediatric Patients with IBD Treated with Azathioprine [J].

Lee, Mi-Na ;

Kang, Ben ;

Choi, So Yoon ;

Kim, Mi Jin ;

Woo, Sook Young ;

Kim, Jong-Won ;

Choe, Yon Ho ;

Lee, Soo-Youn .

INFLAMMATORY BOWEL DISEASES, 2015, 21 (05) :1054-1062

[59] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF THE METHYL AND NUCLEOTIDE METABOLITES OF 6-MERCAPTOPURINE - QUANTITATION OF RED-BLOOD-CELL 6-THIOGUANINE NUCLEOTIDE, 6-THIOINOSINIC ACID AND 6-METHYLMERCAPTOPURINE METABOLITES IN A SINGLE SAMPLE [J].

LENNARD, L ;

SINGLETON, HJ .

JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 583 (01) :83-90

[60] Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations [J].

Lewis, James D. ;

Abramson, Oren ;

Pascua, Monina ;

Liu, Liyan ;

Asakura, Laura M. ;

Velayos, Fernando S. ;

Hutfless, Susan M. ;

Alison, James E. ;

Herrinton, Lisa J. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (11) :1195-1201

← 1 2 3 4 5 6 7 8 9 10 →